CN104650032A - Acridine derivatives, and preparation method and application thereof - Google Patents
Acridine derivatives, and preparation method and application thereof Download PDFInfo
- Publication number
- CN104650032A CN104650032A CN201510037329.XA CN201510037329A CN104650032A CN 104650032 A CN104650032 A CN 104650032A CN 201510037329 A CN201510037329 A CN 201510037329A CN 104650032 A CN104650032 A CN 104650032A
- Authority
- CN
- China
- Prior art keywords
- substituted
- formula
- acridine
- base
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VKVHTZNHLOGHGP-UHFFFAOYSA-N Brc(cc1)ccc1Nc(cc1)ccc1Br Chemical compound Brc(cc1)ccc1Nc(cc1)ccc1Br VKVHTZNHLOGHGP-UHFFFAOYSA-N 0.000 description 2
- ZPVGLKAOLFBDBS-UHFFFAOYSA-N Brc(cc1)cc2c1nc(ccc(Br)c1)c1c2-c(cc1)ccc1-c1ccccc1 Chemical compound Brc(cc1)cc2c1nc(ccc(Br)c1)c1c2-c(cc1)ccc1-c1ccccc1 ZPVGLKAOLFBDBS-UHFFFAOYSA-N 0.000 description 1
- NZMOPAFIHIZWRZ-UHFFFAOYSA-N Brc(cc1)cc2c1nc(ccc(Br)c1)c1c2-c1nc(cccc2)c2cc1 Chemical compound Brc(cc1)cc2c1nc(ccc(Br)c1)c1c2-c1nc(cccc2)c2cc1 NZMOPAFIHIZWRZ-UHFFFAOYSA-N 0.000 description 1
- GRINOTMYADGEDG-UHFFFAOYSA-N Brc(cc1)ccc1-c1c(cc(cc2)Br)c2nc(cc2)c1cc2Br Chemical compound Brc(cc1)ccc1-c1c(cc(cc2)Br)c2nc(cc2)c1cc2Br GRINOTMYADGEDG-UHFFFAOYSA-N 0.000 description 1
- MPSBDMHSWGMEFF-UHFFFAOYSA-N C=[Br]c(cc1)ccc1Nc(cc1)ccc1Br Chemical compound C=[Br]c(cc1)ccc1Nc(cc1)ccc1Br MPSBDMHSWGMEFF-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N OC(c(cc1)ccc1-c1ccccc1)=O Chemical compound OC(c(cc1)ccc1-c1ccccc1)=O NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-N OC(c(cc1)ccc1Br)=O Chemical compound OC(c(cc1)ccc1Br)=O TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N OC(c1nc2ccccc2cc1)=O Chemical compound OC(c1nc2ccccc2cc1)=O LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- DHDHJYNTEFLIHY-UHFFFAOYSA-N c(cc1)ccc1-c1c(ccc2c3nccc2-c2ccccc2)c3ncc1 Chemical compound c(cc1)ccc1-c1c(ccc2c3nccc2-c2ccccc2)c3ncc1 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Electroluminescent Light Sources (AREA)
Abstract
The invention relates to acridine derivatives of which the structure is disclosed as Formula (1). When the electronic transmission layer of the electroluminescent device is prepared from the material provided by the invention, the turn-on voltage of the device can be lowered, the luminescence efficiency of the device can be enhanced, and the service life of the device can be prolonged.
Description
Technical field
The invention belongs to field of organic electroluminescence, be specifically related to a kind of acridine derivatives, its preparation method, and its application in electron transport material.
Background technology
The electron transport material that tradition uses in electroluminescent device is Alq
3, but Alq
3electronic mobility lower (greatly about 10-6cm2/Vs).In order to improve the electronic transmission performance of electroluminescent device, researchist has done a large amount of exploratory study work.LG chemistry reports the derivative of a series of pyrene in the patent specification of China, is used as electric transmission and injecting material, improves the luminous efficiency (publication number CN 101003508A) of device in electroluminescence device.The people such as Cao Yong synthesize FFF-Blm4 (J.Am.Chem.Soc.; (Communication); 2008; 130 (11); 3282-3283) as electric transmission and input horizon material (comparing as negative electrode with independent Al with Ba/Al), significantly improve electron injection and the transmission of device, improve electroluminescence efficiency.Kodak is in United States Patent (USP) (publication number US 2006/0204784 and US 2007/0048545), mention mixed electronic transport layer, adopt the electron transport material of a kind of material of low lumo energy and another kind low bright voltage and other materials to form as metallic substance etc. adulterates.Based on the device of this mixed electronic transport layer, efficiency and life-span etc. are all improved, but are the increase in the complicacy of device fabrication, are unfavorable for reducing OLED cost.The electron transport material of exploitation stability and high efficiency and/or electron injection material, thus reduced bright voltage, improve device efficiency, extend device lifetime, there is very important actual application value.
Summary of the invention
The object of the invention is to the acridine derivatives that proposition one class is novel, this compounds may be used for ORGANIC ELECTROLUMINESCENCE DISPLAYS field.Particularly, this compounds, in display of organic electroluminescence, can be used as electron transport material.When electroluminescent device adopts material of the present invention to prepare electron transfer layer, that can reduce device opens bright voltage, improves the luminous efficiency of device, increases the work-ing life of device.
For achieving the above object, the technical scheme taked of the present invention is as follows:
A kind of acridine derivatives, has such as formula the structure shown in (1):
Wherein: Ar
1and Ar
2identical or different, be independently selected from C
6-C
30substituted or non-substituted aromatic hydrocarbon group, C
6-C
30substituted or non-substituted condensed-nuclei aromatics group, C
5-C
30substituted or non-substituted fused heterocycle group, five yuan, hexa-atomic heterocycle or substituted heterocycle, C
1-C
12substituted or non-substituted aliphatic alkyl group in one; Preferably, described replacement is replaced by alkyl, halogen, cyano group, aryl or heterocyclic aryl.
R
1-R
6identical or different, be independently selected from H, C
1-C
12substituted or non-substituted aliphatic alkyl group, C
6-C
20substituted or non-substituted aromatic hydrocarbon group, C
6-C
20substituted or non-substituted condensed-nuclei aromatics group, C
5-C
20substituted or non-substituted fused heterocycle group, five yuan, hexa-atomic heterocycle or substituted heterocycle.
Described Ar
1and Ar
2be respectively formula (2) to structure formula (11) Suo Shi:
Wherein Ar
3for H, substituted or unsubstituted aryl, substituted or unsubstituted alkyl;
L is singly-bound, substituted or unsubstituted arylidene, substituted or unsubstituted sub-heterocyclic aryl, and preferably, described replacement is replaced by alkyl, halogen, cyano group, aryl or heterocyclic aryl.
Preferably, described compound is structure shown in formula (21)-(56):
The application of described acridine derivatives in organic electroluminescence device, particularly, described acridine derivatives is used as electron transport material.
A kind of organic electroluminescence device, comprises substrate, and forms anode layer, organic luminescence function layer and cathode layer on the substrate successively; Described organic luminescence function layer comprises hole transmission layer, organic luminous layer and electron transfer layer, and described electron transfer layer is prepared from by described acridine derivatives.
Compared with prior art, the advantage of acridine derivatives of the present invention is:
Benzacridine derivative of the present invention connects condensed-nuclei aromatics or electron-withdrawing group on benzacridine precursor structure, belong to typical electron deficiency system, have and good accept electronic capability, it is again coplanar condensed-nuclei aromatics system on space structure, there is applicable HOMO and lumo energy, therefore there is good electron transfer capabilities.Therefore the compound of benzacridine class of the present invention is the electron transport material of a class excellence.
Its molecular weight of electron transport material of the present invention is between 500 and 900, and it has higher glass transition temperature Tg, thus has good thermostability, has good vacuum evaporation film-forming properties simultaneously.
Accompanying drawing explanation
Compound shown in Fig. 1 formula (22) nuclear magnetic spectrogram (
1hNMR);
Compound shown in Fig. 2 formula (27) nuclear magnetic spectrogram (
1hNMR);
Compound shown in Fig. 3 formula (44) nuclear magnetic spectrogram (
1hNMR);
Compound shown in Fig. 4 formula (48) nuclear magnetic spectrogram (
1hNMR).
Embodiment
Basic raw material used in the present invention, two (4-bromophenyl) amine, 4-bromo-benzoic acid, phenylformic acid, naphthoic acid, pyridine-2-formic acid, quinoline-2-formic acid, bromo phenanthrene, bromo anthracene derivant, bromo pyrene, bromo triphenylene etc., can buy in each large industrial chemicals market at home.Various bromo-derivative can make corresponding boronic acid compounds by usual way.
Embodiment 1
The synthesis (reference: Org.Biomol.Chem., 2010,8,326-330) of the bromo-9-phenylacridine of parent 2,7-bis-
Two (4-bromophenyl) amine 26.2g (molecular weight 327,0.08mol), phenylformic acid 9.8g (molecular weight 122,0.08mol), ZnCl
2with 16.1g (molecular weight 134,0.12mol), sand-bath heats 5 hours, stirs simultaneously, temperature 240-260 DEG C.Cooling, dissolves, mixes silica gel, and post is separated (eluent: dichloromethane/ethyl acetate=20:1), obtains 18.2g product, productive rate 55%, molecular weight 413.
Embodiment 2
The synthesis of the bromo-9-of parent 2,7-bis-(pyridine-2-base) acridine
Synthesis step is same as 1 above, and just phenylformic acid is changed into 2-naphthoic acid, other reagent is constant, obtains the bromo-9-of target parent 2,7-bis-(pyridine-2-base) acridine.Reaction path is as follows:
Embodiment 3
The synthesis of the bromo-9-of parent parent 2,7-bis-(quinoline-2-base) acridine
Synthesis step is same as 1 above, and just phenylformic acid is changed into 2-naphthoic acid, other reagent is constant, obtains the bromo-9-of target parent 2,7-bis-(quinoline-2-base) acridine.Reaction path is as follows:
Embodiment 4
The synthesis of the bromo-9-of parent parent 2,7-bis-(2-naphthyl) acridine
Synthesis step is same as 1 above, and just phenylformic acid is changed into 2-naphthoic acid, other reagent is constant, obtains the bromo-9-of target parent 2,7-bis-(2-naphthyl) acridine.Reaction path is as follows:
Embodiment 5
The synthesis of the bromo-9-of parent parent 2,7-bis-(4-bromophenyl) acridine
Synthesis step is same as 1 above, and just phenylformic acid is changed into 4-bromo-benzoic acid, other reagent is constant, obtains the bromo-9-of target parent 2,7-bis-(4-bromophenyl) acridine.Reaction path is as follows:
Embodiment 6
The synthesis of the bromo-9-of parent 2,7-bis-(4-xenyl) acridine
Synthesis step is same as 1 above, and just phenylformic acid is changed into 4-diphenic acid, other reagent is constant, obtains the bromo-9-of target parent 2,7-bis-(4-xenyl) acridine.Reaction path is as follows:
Embodiment 7
The synthesis of compound shown in formula (21)
1000 milliliters of a bite bottles, join magnetic agitation, add parent 2 shown in formula (16), the bromo-9-of 7-bis-(pyridine-2-base) acridine 8.30g (molecular weight 414,0.02mol), 4-(naphthalene-1-base) phenylo boric acid 11.0g (molecular weight 248,0.044mol), Pd (PPh
3)
4usage quantity 2.31g (molecular weight 1154,0.002mol), sodium carbonate 150ml (2M), toluene 150ml, ethanol 150ml.After argon replaces, backflow, with TLC monitoring reaction, react completely after 4 hours, cooling, separates organic layer, evaporate to dryness, pillar layer separation, ethyl acetate/petroleum ether drip washing, obtains compound shown in 11.7g formula (21), molecular weight 660, productive rate 88.4%.
Product MS (m/e): 660, ultimate analysis (C
50h
32n
2): theoretical value C:90.88%, H:4.88%, N:4.24%; Measured value C:90.84%, H:4.90%, N:4.26%.
Embodiment 8
The synthesis of compound shown in formula (22)
Synthesis step is same as embodiment 1, and just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into pyrene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (22).
Product MS (m/e): 656, ultimate analysis (C
50h
28n
2): theoretical value C:91.44%, H:4.30%, N:4.27%; Measured value C:91.47%, H:4.30%, N:4.23%.Compound shown in formula (22) nuclear magnetic spectrogram (
1hNMR) as shown in Figure 1.
Embodiment 9
The synthesis of compound shown in formula (23)
Synthesis step is same as embodiment 1, and just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into pyrene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (23).
Product MS (m/e): 608, ultimate analysis (C
46h
28n
2): theoretical value C:90.76%, H:4.64%, N:4.60%; Measured value C:90.71%, H:4.66%, N:4.63%.
Embodiment 10
The synthesis of compound shown in formula (24)
Synthesis step is same as embodiment 1, and just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into 10-phenylanthracene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (24).
Product MS (m/e): 760, ultimate analysis (C
58h
36n
2): theoretical value C:91.55%, H:4.77%, N:3.68%; Measured value C:91.55%, H:4.77%, N:3.68%.
Embodiment 11
The synthesis of compound shown in formula (25)
Synthesis step is same as embodiment 1, and just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into triphenylene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (25).
Product MS (m/e): 708, ultimate analysis (C
54h
32n
2): theoretical value C:91.50%, H:4.55%, N:3.95%; Measured value C:91.54%, H:4.53%, N:3.93%.
Embodiment 12
The synthesis of compound shown in formula (26)
Synthesis step is same as embodiment 1, and just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into 5-phenylpyridine-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (26).
Product MS (m/e): 562, ultimate analysis (C
40h
26n
4): theoretical value C:85.38%, H:4.66%, N:9.96%; Measured value C:85.42%, H:4.64%, N:9.94%.
Embodiment 13
The synthesis of compound shown in formula (27)
Synthesis step is same as embodiment 1, just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into (2-phenyl-1H-benzo [d] imidazoles-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (27).
Product MS (m/e): 794, ultimate analysis (C
56h
38n
6): theoretical value C:84.61%, H:4.82%, N:10.57%; Measured value C:84.65%, H:4.84%, N:10.51%.Compound shown in formula (27) nuclear magnetic spectrogram (
1hNMR) shown in part Fig. 2.
Embodiment 14
The synthesis of compound shown in formula (28)
Synthesis step is same as embodiment 1, just a kind of raw material 4-(naphthalene-1-base) phenylo boric acid is wherein changed into 4-(1-phenyl-1H-benzo [d] imidazoles-2-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (28).
Product MS (m/e): 794, ultimate analysis (C
56h
38n
6): theoretical value C:84.61%, H:4.82%, N:10.57%; Measured value C:84.62%, H:4.86%, N:10.52%.
Embodiment 15
The synthesis of compound shown in formula (29)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into pyrene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (29).
Product MS (m/e): 706, ultimate analysis (C
54h
30n
2): theoretical value C:91.76%, H:4.28%, N:3.96%; Measured value C:91.81%, H:4.26%, N:3.93%.
Embodiment 16
The synthesis of compound shown in formula (30)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into phenanthrene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (30).
Product MS (m/e): 658, ultimate analysis (C
50h
30n
2): theoretical value C:91.16%, H:4.59%, N:4.25%; Measured value C:91.14%, H:4.62%, N:4.24%.
Embodiment 17
The synthesis of compound shown in formula (31)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 10-phenylanthracene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (31).
Product MS (m/e): 810, ultimate analysis (C
62h
38n
2): theoretical value C:91.82%, H:4.72%, N:3.45%; Measured value C:91.84%, H:4.75%, N:3.41%.
Embodiment 18
The synthesis of compound shown in formula (32)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into triphenylene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (32).
Product MS (m/e): 758, ultimate analysis (C
58h
34n
2): theoretical value C:91.79%, H:4.52%, N:3.69%; Measured value C:91.76%, H:4.58%, N:3.66%.
Embodiment 19
The synthesis of compound shown in formula (33)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into triphenylene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (33).
Product MS (m/e): 690, ultimate analysis (C
52h
38n
2): theoretical value C:90.40%, H:5.54%, N:4.05%; Measured value C:90.43%, H:5.50%, N:4.07%.
Embodiment 20
The synthesis of compound shown in formula (34)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(naphthalene-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (34).
Product MS (m/e): 710, ultimate analysis (C
54h
34n
2): theoretical value C:91.24%, H:4.82%, N:3.94%; Measured value C:91.27%, H:4.80%, N:3.93%.
Embodiment 21
The synthesis of compound shown in formula (35)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into naphthalene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (35).
Product MS (m/e): 558, ultimate analysis (C
42h
26n
2): theoretical value C:90.29%, H:4.69%, N:5.01%; Measured value C:90.33%, H:4.64%, N:5.03%.
Embodiment 22
The synthesis of compound shown in formula (36)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 5-phenylpyridine-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (36).
Product MS (m/e): 612, ultimate analysis (C
44h
28n
4): theoretical value C:86.25%, H:4.61%, N:9.14%; Measured value C:86.23%, H:4.65%, N:9.12%.
Embodiment 23
The synthesis of compound shown in formula (37)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into (2-phenyl-1H-benzo [d] imidazoles-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (37).
Product MS (m/e): 844, ultimate analysis (C
60h
40n
6): theoretical value C:85.28%, H:4.77%, N:9.95%; Measured value C:85.32%, H:4.74%, N:9.94%.
Embodiment 24
The synthesis of compound shown in formula (38)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(quinoline-2-base) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(1-phenyl-1H-benzo [d] imidazoles-2-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (38).
Product MS (m/e): 844, ultimate analysis (C
60h
40n
6): theoretical value C:85.28%, H:4.77%, N:9.95%; Measured value C:85.30%, H:4.73%, N:9.97%.
Embodiment 25
The synthesis of compound shown in formula (39)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(1-naphthyl) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (39).
Product MS (m/e): 735, ultimate analysis (C
57h
37n): theoretical value C:93.03%, H:5.07%, N:1.90%; Measured value C:93.06%, H:5.02%, N:1.92%.
Embodiment 26
The synthesis of compound shown in formula (40)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into naphthalene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (40).
Product MS (m/e): 583, ultimate analysis (C
45h
29n): theoretical value C:92.59%, H:5.01%, N:2.40%; Measured value C:92.55%, H:5.02%, N:2.43%.
Embodiment 27
The synthesis of compound shown in formula (41)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into pyrene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (41).
Product MS (m/e): 731, ultimate analysis (C
57h
33n): theoretical value C:93.54%, H:4.54%, N:1.91%; Measured value C:93.58%, H:4.55%, N:1.87%.
Embodiment 28
The synthesis of compound shown in formula (42)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(2-naphthyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into pyrene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (42).
Product MS (m/e): 705, ultimate analysis (C
55h
31n): theoretical value C:93.59%, H:4.43%, N:1.98%; Measured value C:93.55%, H:4.48%, N:1.97%.
Embodiment 29
The synthesis of compound shown in formula (43)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(2-naphthyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into phenanthrene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (43).
Product MS (m/e): 657, ultimate analysis (C
51h
31n): theoretical value C:93.12%, H:4.75%, N:2.13%; Measured value C:93.10%, H:4.73%, N:2.17%.
Embodiment 30
The synthesis of compound shown in formula (44)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into phenanthrene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (44).
Product MS (m/e): 683, ultimate analysis (C
53h
33n): theoretical value C:93.09%, H:4.86%, N:2.05%; Measured value C:93.06%, H:4.85%, N:2.09%.Compound shown in formula (44) nuclear magnetic spectrogram (
1hNMR) Fig. 3 is seen.
Embodiment 31
The synthesis of compound shown in formula (45)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 10-phenylanthracene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (45).
Product MS (m/e): 835, ultimate analysis (C
65h
41n): theoretical value C:93.38%, H:4.94%, N:1.68%; Measured value C:93.33%, H:4.97%, N:1.70%.
Embodiment 32
The synthesis of compound shown in formula (46)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 10-phenylanthracene-9-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (46).
Product MS (m/e): 759, ultimate analysis (C
59h
37n): theoretical value C:93.25%, H:4.91%, N:1.84%; Measured value C:93.21%, H:4.97%, N:1.82%.
Embodiment 33
The synthesis of compound shown in formula (47)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 2-phenylpyridine-5-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (47).
Product MS (m/e): 637, ultimate analysis (C
47h
31n
3): theoretical value C:88.51%, H:4.90%, N:6.59%; Measured value C:88.56%, H:4.92%, N:6.52%.
Embodiment 34
The synthesis of compound shown in formula (48)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(2-naphthyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 2-phenylpyridine-5-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (48).
Product MS (m/e): 611, ultimate analysis (C
45h
29n
3): theoretical value C:88.35%, H:4.78%, N:6.87%; Measured value C:88.38%, H:4.76%, N:6.86%.Compound shown in formula (48) nuclear magnetic spectrogram (
1hNMR) as shown in Figure 4.
Embodiment 35
The synthesis of compound shown in formula (49)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(2-naphthyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into (2-phenyl-1H-benzo [d] imidazoles-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (49).
Product MS (m/e): 843, ultimate analysis (C
61h
41n
5): theoretical value C:86.81%, H:4.90%, N:8.30%; Measured value C:86.87%, H:4.86%, N:8.27%.
Embodiment 36
The synthesis of compound shown in formula (50)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into (2-phenyl-1H-benzo [d] imidazoles-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (50).
Product MS (m/e): 869, ultimate analysis (C
63h
43n
5): theoretical value C:86.97%, H:4.98%, N:8.05%; Measured value C:86.94%, H:4.97%, N:8.09%.
Embodiment 37
The synthesis of compound shown in formula (51)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-phenylacridine of 7-bis-, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into (2-phenyl-1H-benzo [d] imidazoles-1-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (51).
Product MS (m/e): 793, ultimate analysis (C
57h
39n
5): theoretical value C:86.23%, H:4.95%, N:8.82%; Measured value C:86.26%, H:4.93%, N:8.81%.
Embodiment 38
The synthesis of compound shown in formula (52)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-phenylacridine of 7-bis-, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(1-phenyl-1H-benzo [d] imidazoles-2-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (52).
Product MS (m/e): 793, ultimate analysis (C
57h
39n
5): theoretical value C:86.23%, H:4.95%, N:8.82%; Measured value C:86.26%, H:4.94%, N:8.80%.
Embodiment 39
The synthesis of compound shown in formula (53)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-xenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(1-phenyl-1H-benzo [d] imidazoles-2-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (53).
Product MS (m/e): 869, ultimate analysis (C
63h
43n
5): theoretical value C:86.97%, H:4.98%, N:8.05%; Measured value C:86.95%, H:4.96%, N:8.09%.
Embodiment 40
The synthesis of compound shown in formula (54)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(2-naphthyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into 4-(1-phenyl-1H-benzo [d] imidazoles-2-base) phenylo boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (54).
Product MS (m/e): 843, ultimate analysis (C
61h
41n
5): theoretical value C:86.81%, H:4.90%, N:8.30%; Measured value C:86.85%, H:4.87%, N:8.28%.
Embodiment 41
The synthesis of compound shown in formula (55)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-bromophenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into naphthalene-2-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (55).
Product MS (m/e): 633, ultimate analysis (C
49h
31n): theoretical value C:92.86%, H:4.93%, N:2.21%; Measured value C:92.82%, H:4.95%, N:2.23%.
Embodiment 42
The synthesis of compound shown in formula (56)
Synthesis step is same as embodiment 1, just by raw material 2, the bromo-9-of 7-bis-(pyridine-2-base) acridine changes into 2, the bromo-9-of 7-bis-(4-bromophenyl) acridine, raw material 4-(naphthalene-1-base) phenylo boric acid is changed into naphthalene-1-boric acid, the condition such as other medicine, reagent, reaction, separation is constant, obtains compound shown in formula (56).
Product MS (m/e): 633, ultimate analysis (C
49h
31n): theoretical value C:92.86%, H:4.93%, N:2.21%; Measured value C:92.83%, H:4.91%, N:2.26%.
Here is the Application Example of each compound of the present invention:
Embodiment 43
Conveniently compare the transmission performance of these electron transport materials, the present invention devises a simple electroluminescence device, (EM1 is material of main part as luminescent material to use EM1, and non-luminescent material, object is not pursue high-level efficiency, but verify the possibility of these material practicalities), use efficent electronic transport material Bphen as comparative material.The structure of EM1 and Bphen is respectively:
In the embodiment of the present invention, the structure of organic electroluminescence device is:
Substrate/anode/hole transmission layer (HTL)/organic luminous layer (EL)/electron transfer layer (ETL)/negative electrode.
Substrate can use the substrate in conventional organic luminescence device, such as: glass or plastics.In organic electroluminescence device of the present invention makes, select glass substrate, ITO makes anode material.
Hole transmission layer can adopt various tri-arylamine group material.Hole mobile material selected in organic electroluminescence device of the present invention makes is NPB.NPB structure is:
Negative electrode can adopt metal and composition thereof structure, as Mg:Ag, Ca:Ag etc., is also electron injecting layer/metal-layer structure, as LiF/Al, Li
2the common cathode structures such as O/Al.Cathode material selected in organic electroluminescence device of the present invention makes is LiF/Al.
Compound in the present embodiment is as the electron transport material in organic electroluminescence device, EML is as emitting layer material, prepared multiple organic electroluminescence device altogether, its structure is: ITO/NPB (40nm)/EM1 (30nm)/ETL material (20nm)/LiF (0.5nm)/Al (150nm);
A contrast organic electroluminescence device, electron transport material selects Bphen, and all the other organic electroluminescence devices select material of the present invention.
In the present embodiment, organic electroluminescence device preparation process is as follows:
Sheet glass supersound process in commercial detergent of ITO transparency conducting layer will be coated with, rinse in deionized water, at acetone: ultrasonic oil removing in alcohol mixed solvent, be baked under clean environment and remove moisture content completely, by UV-light and ozone clean, and with low energy positively charged ion bundle bombarded surface;
The above-mentioned glass substrate with anode is placed in vacuum chamber, is evacuated to 1 × 10
-5~ 9 × 10
-3pa, on above-mentioned anode tunic, vacuum evaporation NPB is as hole transmission layer, and evaporation rate is 0.1nm/s, and evaporation thickness is 40nm;
On hole transmission layer, vacuum evaporation EM1 is as the luminescent layer of device, and evaporation rate is 0.1nm/s, and evaporation total film thickness is 30nm;
On luminescent layer, compound shown in vacuum evaporation one laminar (21), (22), (24), (27), (37), (43), (44), (47), (48), (49), (50), (53) or (55) is as the electron transport layer materials of device, with the contrast material of Bphen as device electronic transport layer material, its evaporation rate is 0.1nm/s, and evaporation total film thickness is 20nm;
The upper vacuum evaporation thickness of electron transfer layer (ETL) be the LiF of 0.5nm as electron injecting layer, thickness is the negative electrode of Al layer as device of 150nm.
Organic electroluminescence device performance sees the following form:
Compound number | Require brightness cd/m 2 | Voltage V | Current efficiency cd/A |
Bphen | 1000.00 | 5.1 | 6.0 |
21 | 1000.00 | 4.6 | 6.6 |
22 | 1000.00 | 4.4 | 6.4 |
24 | 1000.00 | 4.4 | 6.7 |
27 | 1000.00 | 4.7 | 6.6 |
37 | 1000.00 | 4.6 | 6.6 |
43 | 1000.00 | 4.5 | 6.5 |
44 | 1000.00 | 4.6 | 6,6 |
47 | 1000.00 | 4.6 | 6.5 |
48 | 1000.00 | 4.7 | 6.7 |
49 | 1000.00 | 4.5 | 6.6 |
50 | 1000.00 | 4.7 | 6.5 |
53 | 1000.00 | 4.6 | 6.5 |
55 | 1000.00 | 4.5 | 6.6 |
Above result shows, new organic materials of the present invention is used for organic electroluminescence device, can effectively reduce bright voltage, and improving current efficiency, is electron transport material of good performance.
Although describe the present invention in conjunction with the embodiments, the present invention is not limited to above-described embodiment, should be appreciated that, under the guiding of the present invention's design, those skilled in the art can carry out various amendment and improvement, and claims summarise scope of the present invention.
Claims (8)
1. an acridine derivatives, is characterized in that, has such as formula the structure shown in (1):
Wherein: Ar
1and Ar
2identical or different, be independently selected from C
6-C
30substituted or non-substituted aromatic hydrocarbon group, C
6-C
30substituted or non-substituted condensed-nuclei aromatics group, C
5-C
30substituted or non-substituted fused heterocycle group, five yuan, hexa-atomic heterocycle or substituted heterocycle, C
1-C
12substituted or non-substituted aliphatic alkyl group in one;
R
1-R
6identical or different, be independently selected from H, C
1-C
12substituted or non-substituted aliphatic alkyl group, C
6-C
20substituted or non-substituted aromatic hydrocarbon group, C
6-C
20substituted or non-substituted condensed-nuclei aromatics group, C
5-C
20substituted or non-substituted fused heterocycle group, five yuan, hexa-atomic heterocycle or substituted heterocycle.
2. acridine derivatives according to claim 1, is characterized in that, Ar
1and Ar
2replaced by alkyl, halogen, cyano group, aryl or heterocyclic aryl respectively.
3. acridine derivatives according to claim 1 and 2, is characterized in that, described Ar
1and Ar
2be respectively formula (2) to structure formula (11) Suo Shi:
Wherein Ar
3for H, substituted or unsubstituted aryl, substituted or unsubstituted alkyl;
L is singly-bound, substituted or unsubstituted arylidene, substituted or unsubstituted sub-heterocyclic aryl.
4. acridine derivatives according to claim 3, is characterized in that, Ar
3replaced by alkyl, halogen, cyano group, aryl or heterocyclic aryl respectively with L.
5. the acridine derivatives according to any one of claim 1-4, is characterized in that, described compound is structure shown in formula (21)-(56):
6. the application of acridine derivatives in organic electroluminescence device described in an any one of claim 1-5.
7. the application of acridine derivatives according to claim 6 in organic electroluminescence device, is characterized in that, described acridine derivatives is used as electron transport material.
8. an organic electroluminescence device, comprises substrate, and forms anode layer, organic luminescence function layer and cathode layer on the substrate successively; Described organic luminescence function layer comprises hole transmission layer, organic luminous layer and electron transfer layer, it is characterized in that:
Described electron transfer layer is prepared from by the acridine derivatives described in any one of claim 1-5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510037329.XA CN104650032B (en) | 2015-01-23 | 2015-01-23 | A kind of acridine derivatives, its preparation method and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510037329.XA CN104650032B (en) | 2015-01-23 | 2015-01-23 | A kind of acridine derivatives, its preparation method and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104650032A true CN104650032A (en) | 2015-05-27 |
CN104650032B CN104650032B (en) | 2018-03-06 |
Family
ID=53241731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510037329.XA Active CN104650032B (en) | 2015-01-23 | 2015-01-23 | A kind of acridine derivatives, its preparation method and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104650032B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397318A (en) * | 2016-09-12 | 2017-02-15 | 长春海谱润斯科技有限公司 | 10-azaanthracene derivative, and preparation method and applications thereof |
EP3182478A1 (en) | 2015-12-18 | 2017-06-21 | Novaled GmbH | Electron injection layer for an organic light-emitting diode (oled) |
CN107235898A (en) * | 2017-07-13 | 2017-10-10 | 长春海谱润斯科技有限公司 | A kind of acridine compounds and organic luminescent device |
CN107311925A (en) * | 2017-07-13 | 2017-11-03 | 长春海谱润斯科技有限公司 | One kind contains acridine compounds and its organic luminescent device |
EP3252837A1 (en) | 2016-05-30 | 2017-12-06 | Novaled GmbH | Organic light emitting diode comprising an organic semiconductor layer |
EP3252841A1 (en) | 2016-05-30 | 2017-12-06 | Novaled GmbH | Organic light emitting diode comprising an organic semiconductor layer |
CN107482132A (en) * | 2017-08-22 | 2017-12-15 | 长春海谱润斯科技有限公司 | A kind of organic luminescent device |
CN111303056A (en) * | 2015-09-30 | 2020-06-19 | 北京鼎材科技有限公司 | Phenazine group-substituted polycyclic aromatic hydrocarbon derivative and application thereof |
CN114671855A (en) * | 2022-04-22 | 2022-06-28 | 云南省烟草质量监督检测站 | Acridine ligand for photothermal material, cuprous iodide cluster-based coordination polymer with photo-thermal property, and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102924431A (en) * | 2012-10-31 | 2013-02-13 | 吉林大学 | Organic luminescent compound containing acridine core and application thereof in electroluminescent device |
CN103304470A (en) * | 2012-03-15 | 2013-09-18 | 海洋王照明科技股份有限公司 | Organic semiconductor material containing naphthalene, preparation method thereof and organic light-emitting device |
-
2015
- 2015-01-23 CN CN201510037329.XA patent/CN104650032B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103304470A (en) * | 2012-03-15 | 2013-09-18 | 海洋王照明科技股份有限公司 | Organic semiconductor material containing naphthalene, preparation method thereof and organic light-emitting device |
CN102924431A (en) * | 2012-10-31 | 2013-02-13 | 吉林大学 | Organic luminescent compound containing acridine core and application thereof in electroluminescent device |
Non-Patent Citations (1)
Title |
---|
ISAO HYODO ET.AL.: "Regioselective C–H bond functionalizations of acridines using organozinc reagents", 《CHEM. COMMUN.》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111303056A (en) * | 2015-09-30 | 2020-06-19 | 北京鼎材科技有限公司 | Phenazine group-substituted polycyclic aromatic hydrocarbon derivative and application thereof |
EP3182478A1 (en) | 2015-12-18 | 2017-06-21 | Novaled GmbH | Electron injection layer for an organic light-emitting diode (oled) |
EP3252837A1 (en) | 2016-05-30 | 2017-12-06 | Novaled GmbH | Organic light emitting diode comprising an organic semiconductor layer |
EP3252841A1 (en) | 2016-05-30 | 2017-12-06 | Novaled GmbH | Organic light emitting diode comprising an organic semiconductor layer |
CN106397318A (en) * | 2016-09-12 | 2017-02-15 | 长春海谱润斯科技有限公司 | 10-azaanthracene derivative, and preparation method and applications thereof |
CN106397318B (en) * | 2016-09-12 | 2018-12-25 | 长春海谱润斯科技有限公司 | A kind of 10- nitrogen (miscellaneous) anthracene derivant and its preparation method and application |
CN107235898A (en) * | 2017-07-13 | 2017-10-10 | 长春海谱润斯科技有限公司 | A kind of acridine compounds and organic luminescent device |
CN107311925A (en) * | 2017-07-13 | 2017-11-03 | 长春海谱润斯科技有限公司 | One kind contains acridine compounds and its organic luminescent device |
CN107482132A (en) * | 2017-08-22 | 2017-12-15 | 长春海谱润斯科技有限公司 | A kind of organic luminescent device |
CN114671855A (en) * | 2022-04-22 | 2022-06-28 | 云南省烟草质量监督检测站 | Acridine ligand for photothermal material, cuprous iodide cluster-based coordination polymer with photo-thermal property, and preparation method and application thereof |
CN114671855B (en) * | 2022-04-22 | 2024-01-23 | 云南省烟草质量监督检测站 | Acridine ligand for photo-thermal material, cuprous iodide cluster-based coordination polymer with photo-thermal property, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104650032B (en) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104650032A (en) | Acridine derivatives, and preparation method and application thereof | |
CN101875637B (en) | Organic material and application thereof in organic electroluminescence devices | |
CN104513662A (en) | Organic light-emitting material and application thereof | |
CN104513246A (en) | Anthra bicarbazole derivative and applications thereof | |
CN104513247A (en) | Benzo [c] benzo [3,4] carbazol derivatives and uses | |
CN106554319B (en) | Quinazoline group-containing derivative and application thereof | |
CN104673276A (en) | Organic luminescent material and application thereof | |
CN103788087B (en) | Anthracene derivatives containing imidazo[1,2,a]pyridine group and applications thereof in OLEDs | |
CN110526901A (en) | A kind of luminous organic material and its application for preparing organic electroluminescence device | |
Gu et al. | Tetrasubstituted adamantane derivatives with arylamine groups: Solution-processable hole-transporting and host materials with high triplet energy and good thermal stability for organic light-emitting devices | |
CN110128403A (en) | Compound, display panel and display device | |
CN104513660A (en) | Organic luminescence material and applications thereof | |
CN104672211A (en) | Benzacridine derivatives, and preparation method and applications thereof | |
CN106554352A (en) | A kind of condensed-nuclei aromatics derivant containing naphthyridines group and its application | |
CN104672240A (en) | Carbazole type derivative and application thereof in organic electroluminescent device | |
CN106554322B (en) | Phenazine derivative and application thereof in organic electroluminescent device | |
CN104649954A (en) | Phenanthrocarbazole derivative and application of phenanthrocarbazole derivative in organic electroluminescence devices | |
CN104710410A (en) | Bibenzimidazole derivative, and preparation method and application thereof | |
CN111233840A (en) | Quinoxaline derivative and application thereof in organic light-emitting device | |
CN106831796B (en) | A kind of electroluminescent organic material and organic photoelectric device | |
CN111303056B (en) | Phenazine group-substituted polycyclic aromatic hydrocarbon derivative and application thereof | |
CN104693174B (en) | Benzacridine derivant, its preparation method and application thereof | |
CN104672226B (en) | A kind of new compound, its preparation method and its application | |
CN104513192B (en) | A kind of benzo anthra [9,1-bc] carbazole derivates and its application | |
CN106554320A (en) | A kind of condensed-nuclei aromatics derivant of quinoxaline group and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |